These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32384200)

  • 1. p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome.
    Lobo J; Alzamora MA; Guimarães R; Cantante M; Lopes P; Braga I; Maurício J; Jerónimo C; Henrique R
    Andrology; 2020 Sep; 8(5):1233-1242. PubMed ID: 32384200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological markers of cisplatin resistance in advanced testicular germ cell tumours.
    García-Velasco A; Durán I; García E; Tarón M; Ballestín C; Castellanos D; Cortés-Funés H; Paz-Ares L
    Clin Transl Oncol; 2012 Jun; 14(6):452-7. PubMed ID: 22634534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of P53 and MDM2 in treatment response of human germ cell tumors.
    Kersemaekers AM; Mayer F; Molier M; van Weeren PC; Oosterhuis JW; Bokemeyer C; Looijenga LH
    J Clin Oncol; 2002 Mar; 20(6):1551-61. PubMed ID: 11896104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
    Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
    Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of melanoma-associated antigen A2 has a clinical significance in embryonal carcinoma and is associated with tumor progression.
    Saeednejad Zanjani L; Razmi M; Fattahi F; Kalantari E; Abolhasani M; Saki S; Madjd Z; Mohsenzadegan M
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):609-631. PubMed ID: 34837545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
    Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
    Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review.
    Romano FJ; Rossetti S; Conteduca V; Schepisi G; Cavaliere C; Di Franco R; La Mantia E; Castaldo L; Nocerino F; Ametrano G; Cappuccio F; Malzone G; Montanari M; Vanacore D; Quagliariello V; Piscitelli R; Pepe MF; Berretta M; D'Aniello C; Perdonà S; Muto P; Botti G; Ciliberto G; Veneziani BM; De Falco F; Maiolino P; Caraglia M; Montella M; De Giorgi U; Facchini G
    Oncotarget; 2016 Dec; 7(51):85641-85649. PubMed ID: 27821802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
    Chovanec M; Cierna Z; Miskovska V; Machalekova K; Svetlovska D; Kalavska K; Rejlekova K; Spanik S; Kajo K; Babal P; Mardiak J; Mego M
    Oncotarget; 2017 Mar; 8(13):21794-21805. PubMed ID: 28423520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression.
    Datta MW; Macri E; Signoretti S; Renshaw AA; Loda M
    Mod Pathol; 2001 May; 14(5):437-42. PubMed ID: 11353054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brachyury oncogene is a prognostic factor in high-risk testicular germ cell tumors.
    Pinto F; Cárcano FM; da Silva ECA; Vidal DO; Scapulatempo-Neto C; Lopes LF; Reis RM
    Andrology; 2018 Jul; 6(4):597-604. PubMed ID: 29749711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors.
    Li B; Cheng Q; Li Z; Chen J
    Cell Cycle; 2010 Apr; 9(7):1411-20. PubMed ID: 20372076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome.
    Jeczen R; Skomra D; Cybulski M; Schneider-Stock R; Szewczuk W; Roessner A; Rechberger T; Semczuk A
    Clin Exp Metastasis; 2007; 24(7):503-11. PubMed ID: 17671841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of relapse in stage I testicular germ cell tumor patients on surveillance: investigation of biomarkers.
    Lobo J; Gillis AJM; van den Berg A; Looijenga LHJ
    BMC Cancer; 2020 Aug; 20(1):728. PubMed ID: 32758242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive tissue markers in testicular germ cell tumors: Immunohistochemical expression of MLH1 and REV-7 proteins.
    Spinos T; Zografos E; Koutsoukos K; Zagouri F; Kosmas C; Driva TS; Goutas D; Gakiopoulou C; Agrogiannis G; Theochari E; Tzavara C; Lazaris AC
    Int Urol Nephrol; 2024 Jun; 56(6):1887-1898. PubMed ID: 38285100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
    Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
    Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
    Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
    Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis regulation and spontaneous apoptosis index of testicular germ cell tumors are associated with differentiation and resistance to systemic treatment.
    Mandoky L; Szende B; Géczi L; Bodrogi I; Kásler M; Bak M
    Anticancer Res; 2008; 28(3A):1641-9. PubMed ID: 18630521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
    Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ
    Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
    Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
    J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors.
    Cavallo F; Feldman DR; Barchi M
    Int J Dev Biol; 2013; 57(2-4):273-80. PubMed ID: 23784838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.